22 min listen
Prof. Hiddo Heerspink: Insights from DAPA-CKD
FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Prof. Hiddo Heerspink: Insights from DAPA-CKD
FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
ratings:
Length:
12 minutes
Released:
Sep 1, 2020
Format:
Podcast episode
Description
In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.
Released:
Sep 1, 2020
Format:
Podcast episode
Titles in the series (94)
Diabetes Research & COVID-19 by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives